Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing
Genes · 2026
DOI: 10.3390/genes17020209 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Genes, 2026. Verfasst von Miguel Carnero-Gregorio und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Spain. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, High-Throughput Nucleotide Sequencing, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background/Objectives: Next-generation sequencing (NGS) has become the standard of care for identifying actionable genomic alterations in non-small cell lung cancer (NSCLC). This study aims to describe the clinicopathological characteristics and genomic landscape of a non-selected cohort of NSCLC patients from the Canary Islands (Spain), analyzed during the first two years of our Molecular Diagnosis Unit’s operation.
Methods
We conducted an observational, retrospective study including 448 tumors from 446 patients diagnosed between March 2023 and March 2025. Genomic profiling was performed using amplicon-based NGS panels (Oncomine™ Focus and Precision Assays) on semiconductor sequencing platforms to detect single-nucleotide variants (SNVs), indels, copy number alterations (CNAs), and gene fusions from DNA and RNA.
Results
Actionable alterations were identified in 55.1% of tumors. The most prevalent alterations were found in TP53 (29.5%), KRAS (27.2%), and EGFR (14.1%), with KRAS G12C being the most frequent variant. Stratified analysis revealed a high prevalence of ALK fusions in patients < 50 years (33.3%). Crucially, and in stark contrast with traditional exclusion criteria, 54.0% of EGFR mutations and 50.0% of ALK fusions were detected in patients with a history of smoking. Concomitant alterations were observed in 34.8% of cases, with TP53 being the most common co-mutation partner.
Conclusions
Our real-world data confirm the feasibility and clinical value of routine NGS testing for NSCLC. The findings highlight specific genomic patterns in this population and demonstrate that smoking status should not preclude comprehensive molecular testing for canonical drivers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Hospital Universitario de Gran Canaria Dr. Negrín, 35010 Las Palmas de Gran Canaria, Spain.
- Fundacion Vithas, Grupo Hospitalario Vithas, Principe de Vergara 109, 28002 Madrid, Spain.
- Fundación Canaria Instituto de Investigación Sanitaria de Canarias, 35012 Las Palmas de Gran Canaria, Spain.
- Dermatology Department, Grupo Hospitalario (CMQ Concheiro), Manuel Olivie 11, 36203 Vigo, Spain.
- Department of Health Sciences, Campus of Vigo, University of Vigo, As Lagoas, 36310 Vigo, Spain.
- European Women's Dermatologic and Venereologic Society (EWDVS), 36700 Tui, Spain.
ORCID-Profile: Miguel Carnero-Gregorio, Enzo Perera-Gordo, Vanesa de la Peña-Castro, Antonio Fernández-Gómez, Carmen Rodríguez-Cerdeira
Zitieren
APA
Carnero-Gregorio, M., Perera-Gordo, E., de la Peña-Castro, V., Fernández-Gómez, A., & Rodríguez-Cerdeira, C. (2026). Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing. Genes. https://doi.org/10.3390/genes17020209
Vancouver
Carnero-Gregorio M, Perera-Gordo E, de la Peña-Castro V, Fernández-Gómez A, Rodríguez-Cerdeira C. Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing. Genes. 2026. doi:10.3390/genes17020209
BibTeX
@article{CarneroGregorio2026,
author = {Carnero-Gregorio, Miguel and Perera-Gordo, Enzo and de la Peña-Castro, Vanesa and Fernández-Gómez, Antonio and Rodríguez-Cerdeira, Carmen},
title = {Genomic Profile of Non-Small Cell Lung Cancer in a Spanish Cohort: A 2-Year Descriptive Study Using Next-Generation Sequencing},
journal = {Genes},
year = {2026},
doi = {10.3390/genes17020209}
}
EUVIMED